Drug Profile
Anastrozole - AstraZeneca
Alternative Names: Arimidex; ICI D 1033; ZD 1033Latest Information Update: 05 Nov 2023
Price :
$50
*
At a glance
- Originator AstraZeneca
- Class Antineoplastics; Nitriles; Small molecules; Triazoles
- Mechanism of Action Aromatase inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed Breast cancer
- Discontinued Female infertility
Most Recent Events
- 09 Feb 2023 Discontinued - Phase-III for Breast cancer (Adjuvant therapy) in Austria (PO)
- 31 May 2021 Queen Mary University of London completes a phase III trial in Breast cancer in Australia, Belgium, Chile, Denmark, Finland, Germany, Hungary, Ireland, Italy, Malta, Portugal, Switzerland, Turkey and the UK (NCT00078832) (EUDRACT-2004-003991-12)
- 17 Feb 2021 Discontinued - Phase-I for Breast cancer (In volunteers) in Japan (PO)